Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …

This review critically appraises the published microbiologic and clinical data on the
treatment of patients with carbapenem‐resistant Acinetobacter baumannii infections …

The purpose of this narrative review is to bring together the most recent epidemiologic,
preclinical, and clinical findings to offer our perspective on best practices for managing …

Carbapenem-resistant Acinetobacter baumannii (CRAB) has become one of the leading
causes of healthcare-associated infections globally, particularly in intensive care units …

Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …

Importance of the field: Acinetobacter baumannii has emerged as a major cause of
healthcare-associated infections. It commonly presents resistance to multiple antimicrobial …

Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter
baumannii (CRAB) infections, but clinical data are limited. This is an observational …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the
most problematic antimicrobial-resistant bacteria. We sought to elucidate the international …